Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma

5Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Purpose: Vismodegib is approved for the treatment of locally advanced basal cell carcinoma (laBCC), but some cases demonstrate intrinsic resistance (IR) to the drug. We sought to assess the frequency of IR to vismodegib in laBCC and its underlying genomic mechanisms. Experimental Design: Response to vismodegib was evaluated in a cohort of 148 laBCC patients. Comprehensive genomic and transcriptomic profiling was performed in a subset of five intrinsically resistant BCC (IR-BCC). Results: We identified that IR-BCC represents 6.1% of laBCC in the studied cohort. Prior treatment with chemotherapy was associated with IR. Genetic events that were previously associated with acquired resistance (AR) in BCC or medulloblastoma were observed in three out of five IR-BCC. However, IR-BCCs were distinct by highly rearranged polyploid genomes. Functional analyses identified hyperactivation of the HIPPO-YAP and WNT pathways at RNA and protein levels in IR-BCC. In vitro assay on the BCC cell line further confirmed that YAP1 overexpression increases the cell proliferation rate. Conclusions: IR to vismodegib is a rare event in laBCC. IR-BCCs frequently harbor resistance mutations in the Hh pathway, but also are characterized by hyperactivation of the HIPPO-YAP and WNT pathways.

References Powered by Scopus

The Sequence Alignment/Map format and SAMtools

41149Citations
N/AReaders
Get full text

Fast and accurate short read alignment with Burrows-Wheeler transform

34863Citations
N/AReaders
Get full text

STAR: Ultrafast universal RNA-seq aligner

29807Citations
N/AReaders
Get full text

Cited by Powered by Scopus

European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023

68Citations
N/AReaders
Get full text

TheMarker: a comprehensive database of therapeutic biomarkers

39Citations
N/AReaders
Get full text

Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors

14Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Yurchenko, A. A., Pop, O. T., Ighilahriz, M., Padioleau, I., Rajabi, F., Sharpe, H. J., … Nikolaev, S. I. (2022). Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma. Clinical Cancer Research, 28(7), 1422–1432. https://doi.org/10.1158/1078-0432.CCR-21-3764

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 1

50%

Researcher 1

50%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 1

25%

Medicine and Dentistry 1

25%

Nursing and Health Professions 1

25%

Economics, Econometrics and Finance 1

25%

Save time finding and organizing research with Mendeley

Sign up for free